Table 2.
Patient characteristics of conversion surgery.
Variables | n = 32 | UR-LA (n = 17) | UR-M (n = 15) | p-Value |
---|---|---|---|---|
Age(years), median (range) | 66 (36–84) | 65 (38–75) | 69 (50–83) | 0.135 |
Male: Female, n (%) | 14 (44): 18 (56) | 7(41):10(59) | 7(47):8(53) | 0.754 |
Ph: Pbt, n (%) | 14 (44): 18 (56) | 9 (53): 8 (47) | 5 (33): 10 (67) | 0.264 |
Tumor Size(mm), median (range) | 36 (25–74) | 35 (25–55) | 40 (27–74) | 0.747 |
Mets site: None:L:P, n (%) | 17 (53): 4 (13):11 (34) | 17 (100): 0 (0):0 (0) | 0(0): 4 (27):11 (73) | <0.0001 |
CA19-9; U/mL, median (range) | 278 (1.2–3400) | 126 (8.4–2200) | 984 (6.6–1953) | 0.209 |
Preoperative CA19-9 | 29.1(1.0–181.9) | 39.7(1.0–181.9) | 19(1.0–73.9) | 0.42 |
Primary Treatment | ||||
GEM or GS | 7 | 4 | 3 | |
GEM + nab-PTX (GnP) | 7 | 4 | 3 | |
S1 or GEM based + ip PTX | 8 | 0 | 8 | |
FOLFIRINOX | 3 | 3 | 0 | |
GEM or S-1 or GS + RT (50.4 Gy) | 7 | 6 | 1 | |
Radiation, n (%) | 13(41) | 11(65) | 2(13) | 0.002 |
Pretreatment period to op; (median, range) | 9.5(4–28) | 10 (4–28) | 9 (6–16) | 0.6207 |
RECIST (CR: PR), n (%) | 1 (3.1%): 31(96.9%) | 0(0):17(100) | 1(7):14(63) | 0.153 |
Operative time(min) | 454(223–866) | 441(223–655) | 467(227–866) | 0.36 |
Intraoperative blood loss(mL) | 1229(207–6301) | 1087(237–2931) | 1255(207–6301) | 0.58 |
Blood transfusion (U) | 0(0–12) | 0(0–7) | 0(0–12) | 0.42 |
PD: DP: DP-CAR: TP, n (%) | 13 (40): 11(34): 4(13): 4(13) | 9(52):4(24):2(12):2(12) | 5(33):7(47):2(13):1(7) | 0.257 |
-CHA/CA/PV resection- | -3(9)/4(13)/15(47)- | -3(18)/2(12)/9(52)- | -0(0)/2(13)/6(40)- | |
Residual tumor (R0: R1), n (%) | 29(91): 3(9) | 16(94):1(6) | 13(87):2(13) | 0.471 |
Postop comp/Mortality (%) | 8(25)/0(0) | 2(12)/0(0) | 6(40)/0(0) | 0.066/0 |
Hospital stay (median, range) | 14 (7–114) | 11 (7–41) | 14 (7–114) | 0.271 |
Evans (I/IIa/IIb/III/IV, (%)) | 1(3)/12(38)/10(31)/8(25)/1 (3) | 1(6)/7(41)/5(29)/4(24)/0 (0) | 0(0)/5(33)/5(33)/4 (27)/1(7) | 0.695 |
Ph: pancreas head, Pbt: pancreas body and tail, Mets: metastasis, L: liver, P: peritoneum, GEM: gemcitabine, GS: S-1 combined with gemcitabine, GnP: nab-paclitaxel combined with gemcitabine, PTX: paclitaxel, RT: radiation, PD: pancreaticoduodenectomy, DP: distal pancreatectomy, DP-CAR: distal pancreatectomy with en-bloc celiac axis resection, CHA: common hepatic artery, CA: celiac artery, PV: portal vein.